Program
HRS-1780
A development code. Also written as “HRS-1780 tablet”, “HRS-1780 tablets” and “HRS-1780 Tablets”.
In Jiangsu HengRui Medicine's pipeline, Mineralocorticoid receptor
. Its studies are mostly in Renal Insufficiency, Chronic · Hypertension · Hyperaldosteronism · Diabetes Mellitus, Type 2, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 76 open or running | phase 3since Feb 12, 2026 | Aug 7, 2023 | Nov 2026phase 2 · NCT07470983 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-1780
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 7, 2023First study: phase 1 study in Renal Insufficiency, ChronicFirst studyNCT06039254 · 27 planned
- Mar 22, 2024Phase 1 study in Renal Insufficiency, ChronicNCT06344936 · 28 planned · China
- Jul 3, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06495931 · 24 enrolled · China
- Feb 12, 2026Phase 3 study in Renal Insufficiency, ChronicPhase 3 reachedNCT07419828 · 5,386 planned · China
- Mar 10, 2026Phase 2 study in HyperaldosteronismNCT07470983 · 61 enrolled · China
- Apr 22, 2026Phase 1 study in Renal Insufficiency, ChronicNCT07557407 · 6 planned · China
- Jul 13, 2026Phase 3 study in Uncontrolled or Resistant HypertensionNCT07708441 · 914 planned · China
Ahead
- Nov 2026Primary completion: phase 2 study in HyperaldosteronismNCT07470983
- Apr 2029Primary completion: phase 3 study in Uncontrolled or Resistant HypertensionNCT07708441
- Apr 2030Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT07419828
TargetBeta
“Mineralocorticoid receptor”the company's pipeline, read by Claude · source
Other programs on NR3C2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| finerenonerule | Bayer | phase 4 | 25 |
| drospirenonerule | estetra | phase 4 | 20 |
| vamorolonerule | reveragen-biopharma-inc | phase 4 | 11 |
| Spironolactonerule | cmp-development-llc | phase 4 | 8 |
| balcinrenonerule | AstraZeneca | phase 3 | 15 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07708441Uncontrolled or Resistant Hypertension · China | 3 | Recruiting | Apr 2029 | 914 |
| NCT07557407Renal Insufficiency, Chronic · China | 1 | Not yet recruiting | Jun 2026 | 6 |
| NCT07470983Hyperaldosteronism · China | 2 | Active, not recruiting | Nov 2026 | 61 |
| NCT07419828Renal Insufficiency, Chronic · China | 3 | Recruiting | Apr 2030 | 5,386 |
| NCT06495931Diabetes Mellitus, Type 2 · China | 1 | Completed | Aug 13, 2024 | 24 |
| NCT06344936Renal Insufficiency, Chronic · China | 1 | Not yet recruiting | Jul 2024 | 28 |
| NCT06039254Renal Insufficiency, Chronic | 1 | Not yet recruiting | Nov 30, 2023 | 27 |
How it is read
Names in the registry
- “HRS-1780 tablet”, 3 entries
- “HRS-1780 tablets”, 2 entries
- “HRS-1780 Tablets”, 1 entry
- “[14C]HRS-1780”, 1 entry
- “HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules”, 1 entry
Codes read as this program: HRS1780.
Conditions, from the studies’ own filings
- Renal Insufficiency, Chronic, 4 studies
- Hypertension, 1 study
- Hyperaldosteronism, 1 study
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.